Press Releases

Date Title and Summary View
Toggle Summary Oxford Immunotec Reports Fourth Quarter and Full Year 2019 Financial Results
Fourth quarter 2019 revenue of $18.1 million, an increase of 18% compared to the prior year period Fourth quarter 2019 gross margin of 78.3%, an increase of 410 basis points from the prior year period Fourth quarter 2019 net loss of $1.6 million, as compared to a pro forma (see tables below) net
View HTML
Toggle Summary Oxford Immunotec to Present at the Cowen and Company 40th Annual Health Care Conference
OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, will present at the Cowen and Company 40 th Annual Health
View HTML
Toggle Summary Oxford Immunotec Schedules Fourth Quarter and Full Year 2019 Earnings Release and Conference Call for March 2, 2020
OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it plans to release fourth quarter and full year 2019 financial results before the open of the
View HTML
Toggle Summary Oxford Immunotec Announces New Data on the Utility of T-SPOT®.CMV in Kidney and Stem Cell Transplant
OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the “Company”), a global, high-growth diagnostics company, today announces two ground-breaking publications in Clinical Infectious Diseases (CID) on the performance of T-SPOT.
View HTML
Toggle Summary Oxford Immunotec Announces Donation in Support of Coronavirus Testing Efforts to Help Differentiate Tuberculosis from the COVID-19
OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 23, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the “Company”), a global, high-growth diagnostics company, today announced they are planning a new initiative to commemorate the coming World Tuberculosis Day, bring the
View HTML
Toggle Summary Oxford Immunotec to Present at the 38th Annual J.P. Morgan Healthcare Conference
OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, will present at the 38th Annual J.P.
View HTML
Toggle Summary Oxford Immunotec to Participate in Two Investor Conferences
OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, is scheduled to participate in the following investor
View HTML
Toggle Summary Oxford Immunotec Reports Third Quarter 2019 Financial Results
Third quarter revenue of $21.2 million, an increase of 32% compared to prior year period Gross margin of 73%, an increase of 150 basis points from the prior year period Positive net income of $0.7 million compared to a net loss of ($3.5) million in prior year period OXFORD, United Kingdom and
View HTML
Toggle Summary Oxford Immunotec Schedules Third Quarter 2019 Earnings Release and Conference Call for November 5, 2019
OXFORD, United Kingdom and MARLBOROUGH, Mass., Oct. 22, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it plans to release third quarter 2019 financial results before the open of the market on
View HTML
Toggle Summary Oxford Immunotec to Participate in Two Upcoming Investor Conferences
OXFORD, United Kingdom and MARLBOROUGH, Mass., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), or the Company, a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, and Matt McLaughlin, Chief Financial
View HTML